Диссертация (1140172), страница 16
Текст из файла (страница 16)
– Vol. 44. – Р. 187–200.86. Le Couteur DG, McLean AM. The aging liver. Drug clearance and an oxygendiffusion barrier hypothesis // Clin Pharmacokinet. – 1998. – Vol. 34. – Р. 359–373.87. Link B, Haschke M, Grignaschi N, Bodmer M, Aschmann YZ, Wenk M,Krähenbühl S. Pharmacokinetics of intravenous and oral midazolam in plasma and111saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping // Br J ClinPharmacol. – 2008. – Vol. 66. – Р. 473–484.88.
Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions inelderly people // Lancet. – 2007 Jul 14. – Vol. 370(9582). – Р. 185-191.89. Margo L., Moretti U., Leone R.. Epidemiology and characteristics of adverse drugreactions caused by drug-drug interactions // Exp Opin Drug Saf. – 2012. – Vol. 11, N 1.– Р. 83–94.90. Marusic S, Bacic-Vrca V, Obreli Neto PR, Franic M, Erdeljic V, Gojo-Tomic N.Actual drug-drug interactions in elderly patients discharged from internalmedicineclinic: a prospective observational study // Eur J Clin Pharmacol. – 2013 Sep.
– Vol. 69,N 9. – Р. 1717-1724.91. McLeod CJ et al. Defining inappropriate practices for prescribing in elderly people:a national consensus panel // CMAJ. – 1997. – Vol. 156. – Р. 385-391.92. McGraw J1, Waller D. Cytochrome P450 variations in different ethnic populations //Expert Opin Drug Metab Toxicol. – 2012 Mar. – Vol. 8, N 3. – Р. 371-382.93. Obreli-Neto PR, Nobili A, de Oliveira Baldoni A, Guidoni CM, de Lyra JúniorDP,Pilger D, Duzanski J, Tettamanti M, Cruciol-Souza JM, Gaeti WP, Cuman RK. Adversedrug reactions caused by drug-drug interactions in elderly outpatients: aprospectivecohort study // Eur J Clin Pharmacol. – 2012 Dec.
– Vol. 68, N 12. – Р. 1667–1676.94. O’Connor MN, Gallagher P, Byrne S, O’Mahony D. Adverse drug reactions in olderpatients during hospitalization: are they predictable? // Age and Ageing. – 2012. – Vol.41, N 3. – Р. 771–776.95. O’Mahony D., O’Sullivan D., Byrne S. et. al. STOPP/START criteria for potentiallyinappropriate prescribing in older people: version 2 // Age Ageing.
– 2015. – Vol. 44, N2. – Р. 213–218.11296. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender,age, ethnicity, and liver microsomes and inducibility in cultured human hepatocytes //Toxicol Appl Pharmacol. – 2004. – Vol. 199. – Р. 193–209.97. Pattanaworasate W, Emmerton L, Pulver L. et al. Comparison of prescribing criteriain hospitalized Australian elderly // Pharm Pract. – 2010. – Vol.
8, N 2. – Р. 132–138.98. PharmGKB. Losartan Pathway, Pharmacokinetics. [Электронный ресурс].Platten HP, Schweizer E, Dilger K, Mikus G, Klotz U. 1998. – Режим доступа: URL:https://www.pharmgkb.org/pathway/PA164713428 (датаобращения: 11.11.2014).99. Pharmacokinetics and the pharmacodynamic action of midazolam in young andelderly patients undergoing tooth extraction // Clin Pharmacol Ther. – 1998. – Vol.
63. –Р. 552–560.100. Report of the Second World Assembly on Ageing (United Nations publicationA/CONF.197/9, Sales No. E.02.IV.4)101. Ruggiero C, Dell"Aquila G, Gasperini B. еt al. ULISSE Study Group. Potentiallyinappropriate drug prescriptions and risk of hospitalization among older, Italian, nursinghome residents: the ULISSE project // Drugs Aging. – 2010. – Vol. 27, N 9. – Р. 747–758.102. Ryan C, O’Mahony D, Kennedy J et al. Potentially inappropriate prescribing in anIrish elderly population in primary care // Br J Clin Pharmacol. – 2009.
– Vol. 68. – Р.936–947.103. Sánchez Muñoz-Torrero JF, Barquilla P, Velasco R, Fernández Capitan Mdel C,Pacheco N, Vicente L, Chicón JL, Trejo S, Zamorano J, Lorenzo Hernandez A. Adversedrug reactions in internal medicine units and associated risk factors // Eur J ClinPharmacol. – 2010 Dec. – Vol. 66, N 12. – Р. 1257–1264.104. Sandwall P, Lo MW, Jonzon B, Dalén P, Furtek C, Ritter M, Alván G, McCrea J,Sjöqvist F. Lack of polymorphism of the conversion of losartan to its active metaboliteE-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and113mephenytoin (cytochrome P450 2C19) // Eur J Clin Pharmacol.–1999.–Vol.
55. – Р.279-283.105. Saverno K, Hines L, Warholak T. et al. Ability of pharmacy clinical decisionsupport software to alert users about clinically-important drug-drug interactions // J AmMed Inform Assoc. – 2011. – Vol. 18, N 1. – Р. 32–37.106. Schmucker DL. Aging and the liver: an update // J Gerontol A Biol Sci Med Sci.–1998. – Vol. 53. – Р. 315–320.107. Schmucker DL. Liver function and phase 1 drug metabolism in the elderly: aparadox // Drugs Aging. – 2001.
– Vol. 18. – Р. 837–851.108. Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, McManus M,Kremers P. Effect of age and gender on in vitro properties of human liver microsomalmono-oxygenases // Clin Pharmacol Ther. – 1990. – Vol. 48.
– Р. 365–374.109. Schwartz JB. Erythromycin breath test results in elderly, very elderly, and frailelderly persons // Clin Pharmacol Ther. – 2006. – Vol. 79. – Р. 440–448.110. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence ofCYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose andmetabolic clerance // Clin Pharmacol Ther.
– 2002. – Vol. 72. – Р. 702–710.111. Sekino K, Kubota T, Okada Y, Yamamoto K, Horiuch R, Kimuru K, Iga T. Effect ofthe single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan inhealthy Japanese subjects // Eur О Clin Pharmacol.–2003 Nov.–Vol. 59, N 8–9.
– Р.589–592.112. Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2inhibitors // Eur J Clin Pharmacol. - 2008. – Vol. 64. – Р. 233–252.113. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividualvariations in human liver cytochrome P-450 enzymes involved in the oxidation of114drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japaneseand 30 Caucasians // J Pharmacol Exp Ther.
– 1994. – Vol. 270. – Р. 414–423.114. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, IngelmanSundberg M. A common novel CYP2C19 gene variant causes ultrarapid drugmetabolism relevant for drug response to proton pump inhibitors and antidepressants //Clin Pharmacol Ther. – 2006. –Vol.
79. – Р. 103–113.115. Simon T, Becquemont L, Hamon B, Nouyrigat E, Chodjania Y, Poirier JM, FunckBrentano C, Jaillon P. Variability of cytochrome P4501A2 activity over time in youngand elderly healthy volunteers // Br J Clin Pharmacol. – 2001. – Vol. 52. – Р. 601–604.116. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450linked drug metabolism in humans: an analysis of 256 subjects with equalhistophathological conditions // Clin Pharmacol Ther. – 1997.
– Vol. 61. – Р. 331–339.117. Thong B., Tan T. Epidemiology and risk factors for drug allergy // Br J ClinPharmacol. – 2011. – Vol. 71, N 5. – Р. 684–500.118. Tsai MH1, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, Fang CK, Wu CS, LuSC, Liu SC, Chen CY, Liu YL. Genetic polymorphisms of cytochrome P450 enzymesinfluence metabolism of the antidepressant escitalopram and treatment response //Pharmacogenomics. – 2010 Apr.
– Vol. 11, N 4. – Р. 537–546.119. Tulner LR, Frankfort SV, Gijsen GJ, Van Campen JP, Koks CH, Beijnen JH. Drugdrug interactions in a geriatric outpatient cohort: prevalence and relevance // DrugsAging. – 2008. – Vol. 25, N 4. – Р. 343–355.120. Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW, Andres R. Antipyrinemetabolism in man: influence of age, alcohol, caffeine, and smoking // Clin PharmacolTher. – 1975. – Vol. 18.
– Р. 425–432.115121. Villesen HH, Banning AM, Petersen RH, Weinelt S, Poulsen JB, Hansen SH,Christrup LL. Pharmacokinetics of morphine and oxycodone following intravenousadministration in elderly patients // Therap Clin Risk Manag. – 2007. – Vol. 3. – Р. 961–976.122. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF,AltmanRB, Klein TE. Pharmacogenomics knowledge for personalized medicine //ClinPharmacol Ther. – 2012 Oct. – Vol. 92, N 4. – Р.
414–417.123. Williamson KM, Patterson JH, McQueen RH, Adams KF, Pieper JA. Effects oferythromycin or rifampin on losartan pharmacokinetics in healthy volunteers // ClinРharmacol Тher. – 1998. – Vol. 63. – Р. 316–323.124. Woodhouse KW, Mutch E, Williams FM, Rawlins MD, James OF. The effect ofage on pathways of drug metabolism in human liver // Age Ageing. – 1984. – Vol. 13. –Р. 328–334.125.
Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML,Eliasson E. Role of CYP2C9 polymorphism in losartan oxidation // Drug metabolismand disposition: the biological fate of chemicals. – 2001. – Vol. 29. – Р. 1051–1056.126. Zang Y, Benet LZ. The gut as a barrier to drug absorption. Combined role of 123.cytochrome P450 and P-glycoprotein // Clin Pharmacokinet. – 2001. – Vol. 40.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
